Trial results

Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes

NCT01572740 on ClinicalTrials.gov · last registry update 2018-02-07

Finished 1 November 2012, after enrolling 257 people. Primary outcome, as filed: Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 16. liraglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

COMPLETED

Phase

P3

Drug

liraglutide

Saxenda, Victoza, Xultophy

Sponsor

Novo Nordisk A/S

Sponsor type

Industry

Enrollment

257

Started

2012-04-05

Primary completion

2012-11-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 16

Conditions studied

Diabetes · Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.